GlassScriptPhysician profile
Steven Zierer
NPI 1366437337
$8,865.12
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $1,067 · 2021: $2,463 · 2022: $1,840 · 2023: $2,139 · 2024: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495 · Education: $15.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.69 |
| Education | $15.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,409.77 | 2019-2024 | Linzess, Viberzi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $881.60 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $817.95 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $624.02 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $611.47 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Pfizer INC. | $417.23 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $348.71 | 2021-2024 | Rebyota, Cimzia |
| Daiichi Sankyo INC. | $303.11 | 2019-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $293.10 | 2019-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $250.97 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $237.12 | 2021 | |
| Celgene Corporation | $218.19 | 2021-2024 | Zeposia |
| Amgen INC. | $203.96 | 2021-2023 | Amjevita, Avsola |
| Qol Medical, LLC | $196.26 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $160.55 | 2020-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $157.99 | 2022-2023 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $146.34 | 2022-2024 | Dupixent |
| Glaxosmithkline, LLC. | $99.44 | 2019-2020 | |
| Organon LLC | $67.09 | 2022-2024 | Renflexis |
| Ucb, INC. | $65.11 | 2019-2020 | |
| Shionogi INC | $55.20 | 2019-2020 | |
| Redhill Biopharma INC. | $50.95 | 2020-2023 | Talicia |
| Braintree Laboratories, INC. | $38.57 | 2019-2021 | |
| Medtronic, INC. | $30.76 | 2022 | |
| Fresenius Kabi USA, LLC | $24.26 | 2023 | Idacio |
| Allergan, INC. | $23.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.27 | 2023 | Cyltezo |
| Endo Pharmaceuticals INC. | $20.22 | 2020 | |
| Genzyme Corporation | $17.60 | 2023 | |
| Lilly USA, LLC | $17.43 | 2023 | |
| Pentax of America, INC. | $16.45 | 2022 | |
| Celltrion USA INC. | $15.21 | 2023 | Yuflyma |
| Capsovision, INC. | $13.45 | 2023 | Capsocam Plus |
| Astrazeneca Pharmaceuticals LP | $11.22 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Zierer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.